Evotec AG and Exscientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-exscientia-announce-partnership-to-discover-bispecific-small-molecule-immuno-oncology-therapeutics-5356